L2-RYC (ATCC® CRL-2180)

Organism: Rattus norvegicus, rat  /  Disease: Carcinoma, Carcinoma, Carcinoma, Carcinoma

Permits and Restrictions

View Permits

Organism Rattus norvegicus, rat
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1
Disease Carcinoma, Carcinoma, Carcinoma, Carcinoma
Age embryo; 10 days gestation
Strain Lewis
Applications
L2-RYC is a yolk sac carcinoma established in 1978 by Dr.
The L2 cell line in which only parietal carcinoma cells could be identified, was established from transplant number 14.
The cell line expresses parietal yolk sac endoderm characteristics in that it synthesizes basement membrane components.
Alpha fetoprotein synthesis could not be demonstrated.
Karyotype The majority of cells had a pseudodiploid chromosome complement; approximately 10% of cells were pseudotetraploid.
Derivation
L2-RYC is a yolk sac carcinoma established in 1978 by Dr. Ulla Wewer from a yolk sac tumor induced by puncturing a Lewis rat embryo through the wall of the uterus at the 10th day of gestation.
A yolk sac carcinoma developed approximately 71/2 months later.
The L2 cell line in which only parietal carcinoma cells could be identified, was established from transplant number 14.
Genes Expressed
laminin; entactin; collagen IV; heparin sulfate proteoglycan; chondroitin sulfate proteoglycan
Tumorigenic Yes
Effects
Yes, in Lewis rats
Comments
L2-RYC is a yolk sac carcinoma established in 1978 by Dr. Ulla Wewer from a yolk sac tumor induced by puncturing a Lewis rat embryo through the wall of the uterus at the 10th day of gestation.
A yolk sac carcinoma developed approximately 71/2 months later.
In the early passages of the parental cell line, designated L1, both visceral and parietal yolk sac carcinomas were present.
L1 cells were injected intraperitoneally into rats and serial transplantations were carried out.
The L2 cell line in which only parietal carcinoma cells could be identified, was established from transplant number 14.
The cell line expresses parietal yolk sac endoderm characteristics in that it synthesizes basement membrane components.
In addition, a noncartilage chondroitin sulfate proteoglycan is synthesized.
Alpha fetoprotein synthesis could not be demonstrated.
The cells must be subcultured frequently and not be allowed to become dense.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Subcultivation Ratio: A subcultivation ratio of 1:5 is recommended
Medium Renewal: Twice per week
Remove spent medium, add fresh 0.25% trypsin, 0.03% EDTA solution, rinse and remove trypsin. Let the culture sit at room temperature (or at 37C) until the cells detach. Add fresh medium, aspirate and dispense into new flasks.
Cryopreservation
Culture medium, 95%; DMSO, 5%
Culture Conditions
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Name of Depositor S Thorgeirsson
Passage History
In the early passages of the parental cell line, designated L1, both visceral and parietal yolk sac carcinomas were present.
Year of Origin 1978
References

Wewer UM, et al. Heparan sulfate proteoglycans made by different basement-membrane- producing tumors have immunological and structural similarities. Differentiation 30: 61-67, 1985. PubMed: 2936642

Wewer U. Characterization of a rat yolk sac carcinoma cell line. Dev. Biol. 93: 416-421, 1982. PubMed: 7141105

Wewer U, et al. Laminin, a noncollagenous component of epithelial basement membranes synthesized by a rat yolk sac tumor. Cancer Res. 41: 1518-1524, 1981. PubMed: 7011537

. . Acta Pathol. Scand. Immunol. Sect. A, Immunol. 92: 275-283, 1984.

Oldberg A, et al. Isolation of a chondroitin sulfate proteoglycan from a rat yolk sac tumor and immunochemical demonstration of its cell surface localization. J. Biol. Chem. 256: 10847-10852, 1981. PubMed: 6793588

Lundstrom M, et al. Immunocytochemical and biochemical characterization of the Heymann nephritis antigenic complex in rat L2 yolk sac cells. Am. J. Pathol. 143: 1423-1435, 1993. PubMed: 8238258

Orlando RA, Farquhar MG. Identification of a cell line that expresses a cell surface and a soluble form of the gp330/receptor-associated protein (RAP) Heymann nephritis antigenic complex. Proc. Natl. Acad. Sci. USA 90: 4082-4086, 1993. PubMed: 8483924

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Wewer UM, et al. Heparan sulfate proteoglycans made by different basement-membrane- producing tumors have immunological and structural similarities. Differentiation 30: 61-67, 1985. PubMed: 2936642

Wewer U. Characterization of a rat yolk sac carcinoma cell line. Dev. Biol. 93: 416-421, 1982. PubMed: 7141105

Wewer U, et al. Laminin, a noncollagenous component of epithelial basement membranes synthesized by a rat yolk sac tumor. Cancer Res. 41: 1518-1524, 1981. PubMed: 7011537

. . Acta Pathol. Scand. Immunol. Sect. A, Immunol. 92: 275-283, 1984.

Oldberg A, et al. Isolation of a chondroitin sulfate proteoglycan from a rat yolk sac tumor and immunochemical demonstration of its cell surface localization. J. Biol. Chem. 256: 10847-10852, 1981. PubMed: 6793588

Lundstrom M, et al. Immunocytochemical and biochemical characterization of the Heymann nephritis antigenic complex in rat L2 yolk sac cells. Am. J. Pathol. 143: 1423-1435, 1993. PubMed: 8238258

Orlando RA, Farquhar MG. Identification of a cell line that expresses a cell surface and a soluble form of the gp330/receptor-associated protein (RAP) Heymann nephritis antigenic complex. Proc. Natl. Acad. Sci. USA 90: 4082-4086, 1993. PubMed: 8483924